Corcept Therapeutics Inc (HAM:HTD)

Q1 2025 Corcept Therapeutics Inc Earnings Call Transcript

May 5, 2025 / 09:00 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Corcept Therapeutics Inc (CORT) reported a revenue increase to $157.2 million in Q1 2025, up from $146.8 million in the same quarter last year.
The company is confident in its future growth prospects, with a significant increase in the prescriber base and patient growth for hypercortisolism treatments.
Corcept Therapeutics Inc (CORT) has expanded its sales force significantly, from 60 to 125 clinical specialists, with plans to reach 175 by year-end.
The company's Catalyst study showed that 1 in 4 patients with difficult-to-control diabetes have hypercortisolism, highlighting a significant market opportunity.
Corcept Therapeutics Inc (CORT) is advancing its oncology portfolio, with positive results from the Rosella trial in platinum-resistant ovarian cancer, showing a 30% reduction in disease progression risk.

Negative

Net income decreased to $20.5 million in Q1 2025 from $27.8 million in the same quarter last year.
The company faced operational challenges with its pharmacy vendor, affecting Q1 results due to insufficient capacity to handle increased prescription volumes.
A transition to authorized generic tablets, which have a lower net price, led to a 13% decrease in average price per tablet.
Corcept Therapeutics Inc (CORT) is involved in ongoing patent litigation with TEA, which could impact future market dynamics.
The company's ALS trial did not meet its primary endpoint, although there was an observed improvement in overall survival, indicating potential regulatory challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CORT.OQ - Corcept Therapeutics Inc
Q1 2025 Corcept Therapeutics Inc Earnings Call
May 05, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to Corsup Therapeutics first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. To remove yourself from the queue, you may press 11 again. I would now like to hand the call over to Aavak Makari, CFO. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello everyone, good afternoon and thank you for joining us. Today we

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.